/Investor DB

Mission Biocapital — 2017 Investments

3 investments dated 2017 · listed companies and verified rows first · show all

Mitokininmitokinin.comSep 2017

Targeting mitochondria for neurodegenerative disease therapies.

BiotechNew York, US

Nicholas Hertz(Director)Doug Crawford(Director)Daniel de Roulet, Jr.(Executive Officer, Director)

Board seatJohannes Fruehauf· per SEC Form D

Co-investorsMission Bay CapitalPfizer Venture Investments

Circle Pharmacirclepharma.comSeries A · Apr 2017 · $2M

Circle Pharma develops cancer treatments using macrocycle therapies designed to reduce side effects compared to conventional therapies.

BiotechDigital HealthHealthtechMedical DevicesSouth San Francisco, US

Matthew P. Jacobson(Co-founder)Scott R. Lokey(Director)David J. Earp(President & CEO)inPaul Park(Executive Officer)

BoardThilo Schroeder(Director)inWalter H. Moos(Director)

Co-investorsBerkeley CatalystHemisphere Ventures LLCJude GomilaLifeforce CapitalMission Bay CapitalNextech Invest+4 more

Sentien Biotechnologiessentienbiotech.comSeries A · Apr 2017 · $12M

BiotechMedford, US

Biju Parekkadan(Director)Brian Miller(Executive Officer, Director)

BoardMartin Heidecker(Director)Greg Bailey(Director)Rich Ganz(Director)

Co-investorsChiesi VenturesBioInnovation Capital

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.